Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(3)

MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 Paclitaxelは一種microtubulポリマー(polymer)安定剤で、人間内皮細胞の中にIC50値が0.1 pMです。
ターゲット

Microtubule (human endothelial cells)

IC50

0.1 pM [1]

In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfqO5FXUUN3ME2wMlAxODJ6NzFOwG0> NGDqdWhUSU6JRWK=
LC-2-ad MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M362UmlEPTB;MD6wNFA{OTdizszN NGi5e5JUSU6JRWK=
RL95-2 NXTJVGhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPnTWM2OD1yLkCwNFY3QCEQvF2= M3[wRXNCVkeHUh?=
MZ1-PC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPkRYdGUUN3ME2wMlAxODd{OTFOwG0> MnfyV2FPT0WU
TE-8 NUiyZpV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMECxNVch|ryP MXvTRW5ITVJ?
SW954 M3KxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGraOY9KSzVyPUCuNFAyOTlizszN NIe1OJNUSU6JRWK=
TE-11 NID2[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMECxNlMh|ryP MmTSV2FPT0WU
PSN1 NFPiOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG0WWFKSzVyPUCuNFAyOyEQvF2= MmryV2FPT0WU
MOLT-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7NTWM2OD1yLkCwNVQ6KM7:TR?= NWX5Z45uW0GQR1XS
697 M1rPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMECxOUDPxE1? M2iyTHNCVkeHUh?=
ETK-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLJUm5RUUN3ME2wMlAxOTV{IN88US=> M4[xeXNCVkeHUh?=
TE-10 NUHqbZd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fI[WlEPTB;MD6wNFE2PCEQvF2= NGfacphUSU6JRWK=
HUTU-80 NUPHWFNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPEWm5KSzVyPUCuNFAyPjhizszN MmrsV2FPT0WU
NTERA-S-cl-D1 NFTkVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\4TWM2OD1yLkCwNlA6KM7:TR?= NFXLSHdUSU6JRWK=
MFH-ino NILNeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXiO49yUUN3ME2wMlAxOjZ6IN88US=> MYDTRW5ITVJ?
IA-LM NYHJ[mxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzhVmlKSzVyPUCuNFAzQCEQvF2= MXjTRW5ITVJ?
MC116 NGmxb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHYTWM2OD1yLkCwNlg6KM7:TR?= NGXsTXpUSU6JRWK=
RKO NFSwW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjRTWM2OD1yLkCwNlk5KM7:TR?= NWK4O49vW0GQR1XS
MRK-nu-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn2eXJKSzVyPUCuNFAzQTlizszN MlGxV2FPT0WU
VA-ES-BJ NUfMeo9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMECzJO69VQ>? MnrlV2FPT0WU
KALS-1 NITmemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXwTWM2OD1yLkCwN|A5KM7:TR?= MVHTRW5ITVJ?
BB30-HNC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDCWlhKSzVyPUCuNFA{OTRizszN Ml3XV2FPT0WU
ACN NWflRpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TaNGlEPTB;MD6wNFMyPiEQvF2= MWnTRW5ITVJ?
TE-9 NFnodG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi2TWM2OD1yLkCwN|I3KM7:TR?= NGKycYFUSU6JRWK=
SIG-M5 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS5OlBKSzVyPUCuNFA{OjdizszN NYHOVWVFW0GQR1XS
no-10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjDSGVKSzVyPUCuNFA{PjJizszN M2DPWHNCVkeHUh?=
EW-1 NXfjPZI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnFbnhKSzVyPUCuNFA{PzFizszN MVPTRW5ITVJ?
SK-LMS-1 NWSyRWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTkXIlyUUN3ME2wMlAxPDBzIN88US=> M1vLVnNCVkeHUh?=
GT3TKB M{K2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;JTWM2OD1yLkCwOFM1KM7:TR?= NHLIOHFUSU6JRWK=
ES4 M{izVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2P4R2lEPTB;MD6wNFQ1QSEQvF2= Mn;qV2FPT0WU
IMR-5 NXPqc2xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXITWM2OD1yLkCwOFUh|ryP MXfTRW5ITVJ?
NCI-H1648 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrPWpBKSzVyPUCuNFA1PjlizszN NWrOWYd1W0GQR1XS
MV-4-11 MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vxUGlEPTB;MD6wNFQ4PSEQvF2= MYnTRW5ITVJ?
SK-UT-1 M1rJWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\NTWM2OD1yLkCwOFgh|ryP NVfaUXRkW0GQR1XS
NB13 Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYC4UpVYUUN3ME2wMlAxPDlzIN88US=> NH\LU2JUSU6JRWK=
DJM-1 M{H3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;3TWM2OD1yLkCwOVMh|ryP NU\BNXY6W0GQR1XS
ES8 NFzJN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXQSYl1UUN3ME2wMlAxPTN6IN88US=> M1WxfHNCVkeHUh?=
TE-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjrcFBKSzVyPUCuNFA2PyEQvF2= NU\vem0yW0GQR1XS
KS-1 MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13SeGlEPTB;MD6wNFU5OiEQvF2= MYLTRW5ITVJ?
TE-1 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvaV5B6UUN3ME2wMlAxPjB4IN88US=> MW\TRW5ITVJ?
ATN-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn4SmhKSzVyPUCuNFA3ODlizszN M3PT[nNCVkeHUh?=
A4-Fuk NYDXeI9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojNTWM2OD1yLkCwOlEyKM7:TR?= M3KwUHNCVkeHUh?=
ALL-PO NYCxe4RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\wSFdKSzVyPUCuNFA3OyEQvF2= M17GWHNCVkeHUh?=
BE-13 NWHoV2JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nmfGlEPTB;MD6wNFY{PiEQvF2= M3r2UnNCVkeHUh?=
KM12 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3hVYlKSzVyPUCuNFA3OzdizszN NVfqcmFlW0GQR1XS
NOS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG3PWxKSzVyPUCuNFA3PSEQvF2= M4nGNXNCVkeHUh?=
SW962 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMEC2OlIh|ryP MkjvV2FPT0WU
OCUB-M NUjJ[W85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnUeYlKSzVyPUCuNFA3PjJizszN NEHtWnNUSU6JRWK=
NCI-H510A M4DQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEC2OlUh|ryP Mn60V2FPT0WU
EW-16 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEC2PVQh|ryP M4DPZnNCVkeHUh?=
KGN MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\CToRKSzVyPUCuNFA4OTJizszN MnO5V2FPT0WU
LS-411N M3nsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm0U4lKSzVyPUCuNFA4OTdizszN MlzoV2FPT0WU
Becker Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NViyWWNRUUN3ME2wMlAxPzJizszN NF\CdnBUSU6JRWK=
HC-1 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXsTWM2OD1yLkCwO|IyKM7:TR?= M125e3NCVkeHUh?=
CESS MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHXNo1iUUN3ME2wMlAxPzN5IN88US=> NGDk[WlUSU6JRWK=
KURAMOCHI MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXoTWM2OD1yLkCwO|Q5KM7:TR?= NH\tVWJUSU6JRWK=
TGBC24TKB MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vYZWlEPTB;MD6wNFc2OiEQvF2= M3XsPHNCVkeHUh?=
SW982 NVPmSpB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrjTJZWUUN3ME2wMlAxPzZ4IN88US=> MUDTRW5ITVJ?
HCE-4 NXG2e5c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXsTWM2OD1yLkCwO|Y4KM7:TR?= M{DGdHNCVkeHUh?=
LOUCY NX7TZpNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEC3O|Uh|ryP NWfSTpFUW0GQR1XS
8-MG-BA NEnDZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMEC3PVYh|ryP MXTTRW5ITVJ?
HT-144 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD2TWM2OD1yLkCwPEDPxE1? NYWwSY8xW0GQR1XS
LXF-289 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknoTWM2OD1yLkCwPFE5KM7:TR?= MULTRW5ITVJ?
RS4-11 NI\T[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnzUlNKSzVyPUCuNFA5OzZizszN NFXsRmJUSU6JRWK=
DEL MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrOTWM2OD1yLkCwPFQ2KM7:TR?= MnHhV2FPT0WU
OCI-AML2 NEjTWoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;pR3VKSzVyPUCuNFA5PTJizszN MmftV2FPT0WU
CCRF-CEM NYHhTlM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvtbY1KSzVyPUCuNFA5PzFizszN MWjTRW5ITVJ?
A388 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTwUFRKSzVyPUCuNFA5PzRizszN NIPwWVBUSU6JRWK=
KNS-42 MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEC4PVEh|ryP NYHyZZVQW0GQR1XS
OVCAR-4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\UdIZuUUN3ME2wMlAxQTB2IN88US=> NIfvOFdUSU6JRWK=
NCI-H1355 M{PueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTKdW01UUN3ME2wMlAxQTF2IN88US=> MWXTRW5ITVJ?
BL-70 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnrPJF[UUN3ME2wMlAxQTNizszN MoXWV2FPT0WU
BL-41 M1rycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[wZWlEPTB;MD6wNFk{PCEQvF2= MVzTRW5ITVJ?
A101D M2jsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMEC5OkDPxE1? MXzTRW5ITVJ?
HL-60 M1jQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MniwTWM2OD1yLkCwPVY3KM7:TR?= M3vRNHNCVkeHUh?=
COR-L279 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7uXFN3UUN3ME2wMlAxQTl7IN88US=> MoPYV2FPT0WU
NCI-SNU-16 M1K4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q4d2lEPTB;MD6wNVAxQCEQvF2= NVXSOWFEW0GQR1XS
Calu-6 NGD4fZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXER3hKSzVyPUCuNFExOTJizszN Mn;1V2FPT0WU
SR NWHt[4E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEGwNlYh|ryP M1;xSXNCVkeHUh?=
QIMR-WIL NVH2XW9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXCe5BnUUN3ME2wMlAyODN|IN88US=> MmWwV2FPT0WU
LB647-SCLC M17xPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DCS2lEPTB;MD6wNVA2OSEQvF2= NWryfnJCW0GQR1XS
RPMI-8226 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEGxNFIh|ryP NYDZdohEW0GQR1XS
SK-PN-DW NFTaTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoOwTWM2OD1yLkCxNVEzKM7:TR?= MXLTRW5ITVJ?
SF268 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMEGxOVEh|ryP Mo\qV2FPT0WU
HD-MY-Z NXvWXoxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\iU2lEPTB;MD6wNVE3OyEQvF2= NF76[FRUSU6JRWK=
DOHH-2 MmnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTmRol5UUN3ME2wMlAyOjB|IN88US=> NHraNHRUSU6JRWK=
SCC-3 M2S3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zmfmlEPTB;MD6wNVIxPCEQvF2= NXXLcVAzW0GQR1XS
ST486 NWDmdJdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF6weItKSzVyPUCuNFEzODRizszN MYnTRW5ITVJ?
NALM-6 M3e0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEGyNVQh|ryP MXvTRW5ITVJ?
NCI-H1436 NH7pWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTwXWJSUUN3ME2wMlAyOjNzIN88US=> Mlq2V2FPT0WU
KE-37 NX3EWppIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfSXFFKSzVyPUCuNFEzOzRizszN MUHTRW5ITVJ?
RPMI-8402 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMEGyOVYh|ryP Mn;rV2FPT0WU
RXF393 M{TNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnMN2ZNUUN3ME2wMlAyOjV5IN88US=> M1\Fe3NCVkeHUh?=
KARPAS-45 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnkR2RKSzVyPUCuNFEzPyEQvF2= MmnwV2FPT0WU
HOP-62 NGn3eolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jW[2lEPTB;MD6wNVI4PiEQvF2= NGrOR3pUSU6JRWK=
ES1 NI\0SZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC4cZNvUUN3ME2wMlAyOjh6IN88US=> M2nYTHNCVkeHUh?=
L-363 NYjIOVB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG3VFVKSzVyPUCuNFE{PTFizszN NHXucodUSU6JRWK=
GI-1 NUP3VXBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS2UXpRUUN3ME2wMlAyOzd|IN88US=> M1TiWnNCVkeHUh?=
CTV-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEG0O|gh|ryP NHe1SVdUSU6JRWK=
TE-5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXVVGdKSzVyPUCuNFE1QTZizszN NVvtZW9iW0GQR1XS
SNU-C2B NF\CXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEG0PVYh|ryP Ml7BV2FPT0WU
K-562 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPTdGdOUUN3ME2wMlAyPTF4IN88US=> NVnRboNjW0GQR1XS
SNB75 NXjFOnRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fP[mlEPTB;MD6wNVU1KM7:TR?= NEjaNIZUSU6JRWK=
MOLT-13 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEG2N|ch|ryP M{nHc3NCVkeHUh?=
LS-123 M{f5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fNdmlEPTB;MD6wNVY3PCEQvF2= MUDTRW5ITVJ?
NCI-SNU-5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHztb5VKSzVyPUCuNFE4ODFizszN M1XlfXNCVkeHUh?=
Daudi MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4noZWlEPTB;MD6wNVcxQCEQvF2= M4mzRXNCVkeHUh?=
A253 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TCbmlEPTB;MD6wNVc{QCEQvF2= MXTTRW5ITVJ?
TGBC1TKB MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLweXVRUUN3ME2wMlAyPzV{IN88US=> MmjPV2FPT0WU
SJSA-1 NFKyTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PDUGlEPTB;MD6wNVc3PyEQvF2= MoO4V2FPT0WU
NCCIT M17ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHMZWFKSzVyPUCuNFE4PjlizszN Ml:5V2FPT0WU
NCI-H69 M2qw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHGRZNKSzVyPUCuNFE4PzhizszN M1zofnNCVkeHUh?=
SH-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q1ZWlEPTB;MD6wNVg6PSEQvF2= NVG0NYVxW0GQR1XS
HCC1187 NHThZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEG5NlQh|ryP NGG1OHRUSU6JRWK=
HCC1599 NVu4SIE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPkfnNLUUN3ME2wMlAzODJizszN M3;CdXNCVkeHUh?=
ONS-76 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jZcGlEPTB;MD6wNlA{PiEQvF2= NF7KRVRUSU6JRWK=
KU812 NECyVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEKwN|kh|ryP NUHHXm5YW0GQR1XS
ML-2 NXLDZo1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jQT2lEPTB;MD6wNlA1PyEQvF2= MnLCV2FPT0WU
HCE-T MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PVTGlEPTB;MD6wNlA6OiEQvF2= MUjTRW5ITVJ?
NCI-H446 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMEKxNVIh|ryP Mo\0V2FPT0WU
RPMI-6666 NV;yWINNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rVV2lEPTB;MD6wNlE1QSEQvF2= M{PPW3NCVkeHUh?=
MOLT-16 NVKyeJN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7nTWM2OD1yLkCyNVU{KM7:TR?= M3vGPHNCVkeHUh?=
JiyoyeP-2003 M4i5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXjTWM2OD1yLkCyNVc3KM7:TR?= NGXiO5ZUSU6JRWK=
MHH-PREB-1 NFe4N|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILCVopKSzVyPUCuNFIyQTFizszN NV7GUFY4W0GQR1XS
MC-CAR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEKzNlYh|ryP NVnXfodoW0GQR1XS
BC-3 M3LscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS3W5NKSzVyPUCuNFI{PDRizszN MUHTRW5ITVJ?
KINGS-1 MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi4OZNKSzVyPUCuNFI{PTVizszN MmXKV2FPT0WU
PF-382 NEfMe3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HmSWlEPTB;MD6wNlM4QCEQvF2= NFO1OJRUSU6JRWK=
J-RT3-T3-5 M4DWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHSdGtzUUN3ME2wMlAzOzh|IN88US=> NGTKdZFUSU6JRWK=
SF539 NV\lRo5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEK0NFEh|ryP Mo\4V2FPT0WU
LB831-BLC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLSToFKSzVyPUCuNFI1QDVizszN MXzTRW5ITVJ?
DMS-114 MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEK1NFIh|ryP M4H0XHNCVkeHUh?=
LB1047-RCC Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvxR4NEUUN3ME2wMlAzPTFizszN M2HXPXNCVkeHUh?=
LB771-HNC NUj1fVBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom3TWM2OD1yLkCyOVM1KM7:TR?= MVjTRW5ITVJ?
BB65-RCC M1j6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMEK1N|Qh|ryP M1zrc3NCVkeHUh?=
BV-173 MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEK1OVQh|ryP MkntV2FPT0WU
ARH-77 M4PjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnITWM2OD1yLkCyOlAyKM7:TR?= M{XTWnNCVkeHUh?=
IST-MEL1 M3rCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HXdWlEPTB;MD6wNlYzOyEQvF2= NHK2dHdUSU6JRWK=
NB1 NX3Qe|V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j1XGlEPTB;MD6wNlY5PyEQvF2= NFnZWIlUSU6JRWK=
EoL-1-cell MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\ETWM2OD1yLkCyOlg5KM7:TR?= M4LkPHNCVkeHUh?=
KY821 NFOzV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfNXHpKSzVyPUCuNFI3QTdizszN M2juUnNCVkeHUh?=
CMK NUDXTVF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjBTWM2OD1yLkCyO|M1KM7:TR?= MYfTRW5ITVJ?
NCI-H2126 MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzxTWM2OD1yLkCyO|Y5KM7:TR?= NHfhVlFUSU6JRWK=
NCI-H526 M17UWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C0OGlEPTB;MD6wNlg6OSEQvF2= NYj3VWJ4W0GQR1XS
COLO-684 NWLrSlFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEK5NFgh|ryP NYHvOHN{W0GQR1XS
NCI-H747 NXzWXWVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLZO5hKSzVyPUCuNFI6OzNizszN NHfuNGpUSU6JRWK=
JAR M1;O[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG0O|E3UUN3ME2wMlAzQTR4IN88US=> MUDTRW5ITVJ?
MEG-01 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHudJVKSzVyPUCuNFI6PzhizszN MmPhV2FPT0WU
MONO-MAC-6 M1fLNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXQZ3drUUN3ME2wMlA{ODJ|IN88US=> MYnTRW5ITVJ?
IST-SL1 M{Ttb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jtUGlEPTB;MD6wN|A1OiEQvF2= MlPDV2FPT0WU
CPC-N MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PTTGlEPTB;MD6wN|A4QSEQvF2= MorZV2FPT0WU
NCI-H1963 M2HqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TV[WlEPTB;MD6wN|E{OSEQvF2= MoS0V2FPT0WU
K052 M3K0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTnTWM2OD1yLkCzNlQ4KM7:TR?= M3fPcnNCVkeHUh?=
KM-H2 M4H0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPyTWM2OD1yLkCzN|A4KM7:TR?= MU\TRW5ITVJ?
TE-12 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKzTWM2OD1yLkCzN|A6KM7:TR?= MWPTRW5ITVJ?
TK10 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULuOZdIUUN3ME2wMlA{OzV4IN88US=> MVjTRW5ITVJ?
NMC-G1 Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkOxTWM2OD1yLkCzOFUzKM7:TR?= NImzSo9USU6JRWK=
no-11 M33De2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jQ[WlEPTB;MD6wN|Q4QCEQvF2= MY\TRW5ITVJ?
NCI-H524 NYTr[HB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEO1Nlkh|ryP M3HWfXNCVkeHUh?=
MHH-CALL-2 NFrOUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDpcG9QUUN3ME2wMlA{PTZ{IN88US=> M2\QVHNCVkeHUh?=
GB-1 NXjOUJlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLFb2lwUUN3ME2wMlA{PiEQvF2= NFr0UWRUSU6JRWK=
OPM-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX4dXExUUN3ME2wMlA{Pjd|IN88US=> MYrTRW5ITVJ?
RH-1 M4DUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLhZ4FWUUN3ME2wMlA{QDF7IN88US=> NHG4VHpUSU6JRWK=
NCI-H64 M3vXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMEO4OVch|ryP Mnz5V2FPT0WU
EVSA-T Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMEO5NlMh|ryP Mm\RV2FPT0WU
KARPAS-299 NXXHXFlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTVfXVzUUN3ME2wMlA{QThizszN M3r1NnNCVkeHUh?=
MZ7-mel M13lWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrsTWM2OD1yLkC0NFQh|ryP MUHTRW5ITVJ?
LB373-MEL-D Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMESxNFUh|ryP NYDkboJyW0GQR1XS
HEL NE\Yc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7CTWM2OD1yLkC0NVQh|ryP MnqxV2FPT0WU
SW872 NVrUNZBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3NSZNKSzVyPUCuNFQzOSEQvF2= MoXvV2FPT0WU
DU-4475 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjvVG1KSzVyPUCuNFQzPDRizszN M3G0eXNCVkeHUh?=
IST-SL2 NYHmVXQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf2dFZRUUN3ME2wMlA1Ojd3IN88US=> Mm\KV2FPT0WU
NCI-H82 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwMESzNFch|ryP Mn2wV2FPT0WU
LC4-1 MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLpTWM2OD1yLkC0N|UyKM7:TR?= M1;GbXNCVkeHUh?=
HDLM-2 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXFTWM2OD1yLkC0N|kzKM7:TR?= MX3TRW5ITVJ?
MMAC-SF Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMES1N|Qh|ryP M3P6VnNCVkeHUh?=
L-540 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu1S5ZIUUN3ME2wMlA1PjN7IN88US=> MmDiV2FPT0WU
MZ2-MEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\GWmJkUUN3ME2wMlA1PzR{IN88US=> MkXDV2FPT0WU
LU-134-A NGfTW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmm5TWM2OD1yLkC0O|c{KM7:TR?= Ml\XV2FPT0WU
UACC-257 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX60VZBSUUN3ME2wMlA1QDR7IN88US=> NUOzV5ZwW0GQR1XS
NCI-H1581 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nqWGlEPTB;MD6wOFk2OyEQvF2= MoC4V2FPT0WU
NB17 M2SyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33DSmlEPTB;MD6wOFk4QSEQvF2= M32xZnNCVkeHUh?=
SBC-1 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\2TWM2OD1yLkC1NFQzKM7:TR?= MWrTRW5ITVJ?
TALL-1 NGPvOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:3[GlKSzVyPUCuNFUxPDVizszN MVrTRW5ITVJ?
NCI-H1304 NWTjbFJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr0b|JmUUN3ME2wMlA2OjB6IN88US=> M1jYdHNCVkeHUh?=
NEC8 NXjRfHMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMEWyPFYh|ryP M{L2SnNCVkeHUh?=
CAL-148 M3nMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2exe2lEPTB;MD6wOVQ{QSEQvF2= MUnTRW5ITVJ?
CGTH-W-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPXTWM2OD1yLkC1OFQ6KM7:TR?= MWjTRW5ITVJ?
NCI-H889 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEW1PVIh|ryP MlH0V2FPT0WU
GR-ST NUPlXYhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vWWGlEPTB;MD6wOVYzOSEQvF2= MmPiV2FPT0WU
KARPAS-422 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXVTWM2OD1yLkC1OlUh|ryP MlfqV2FPT0WU
RPMI-8866 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTkTWM2OD1yLkC1O|EzKM7:TR?= NW\LfoN4W0GQR1XS
SCLC-21H NXfReGV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMEW4PFQh|ryP M{fQSnNCVkeHUh?=
COR-L88 NEDSOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPlTnpKSzVyPUCuNFU6OjdizszN NWPKW3pHW0GQR1XS
LU-139 M4jW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\5PWFKSzVyPUCuNFU6QDZizszN NVnCSnVbW0GQR1XS
SF126 NInNZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDOTWM2OD1yLkC2NVM{KM7:TR?= MonMV2FPT0WU
NCI-H1882 M3:0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O0OGlEPTB;MD6wOlQzPCEQvF2= M{PHXHNCVkeHUh?=
EW-24 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XhfmlEPTB;MD6wOlQ5OyEQvF2= M4L2OnNCVkeHUh?=
CP67-MEL M2Dxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwME[4NUDPxE1? MVPTRW5ITVJ?
DG-75 NHnkV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzCT3hzUUN3ME2wMlA3QDl7IN88US=> M{jDOXNCVkeHUh?=
LOXIMVI M17JU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXexO2pkUUN3ME2wMlA4ODJ6IN88US=> NEnYZYxUSU6JRWK=
HH MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PsRmlEPTB;MD6wO|E2PyEQvF2= M2f4VnNCVkeHUh?=
K5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrF[|NKSzVyPUCuNFczOjZizszN MWDTRW5ITVJ?
EC-GI-10 NEjqZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXkTWM2OD1yLkC3NlU4KM7:TR?= M13mPHNCVkeHUh?=
SK-N-DZ NEPPR|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PVNmlEPTB;MD6wO|MxPyEQvF2= MmGzV2FPT0WU
A3-KAW NIfTeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnlVWFKSzVyPUCuNFc{PTFizszN MXHTRW5ITVJ?
MLMA MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMEe0OlUh|ryP NV\zTZQ5W0GQR1XS
LB996-RCC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvsUW95UUN3ME2wMlA4PzB5IN88US=> MVPTRW5ITVJ?
OS-RC-2 NGXZPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3aNoJKSzVyPUCuNFc4PDhizszN NILCWnZUSU6JRWK=
CTB-1 NIq5TWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf3T3U{UUN3ME2wMlA4QDFizszN NHPzPFFUSU6JRWK=
IST-MES1 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTLSo5NUUN3ME2wMlA4QTF{IN88US=> NGrheG5USU6JRWK=
LS-1034 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn60TWM2OD1yLkC4NFM2KM7:TR?= NXrtZlFwW0GQR1XS
HT NG\DV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fJcGlEPTB;MD6wPFA5PiEQvF2= M{jZO3NCVkeHUh?=
NCI-H2141 M3vVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMEixJO69VQ>? MVnTRW5ITVJ?
LB2518-MEL NWrMOXljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy5RYNKSzVyPUCuNFgyPDFizszN MknkV2FPT0WU
GI-ME-N M{jQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDwUnlKSzVyPUCuNFg1PTJizszN NGHObHRUSU6JRWK=
TGW MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C1cWlEPTB;MD6wPFYxPyEQvF2= NFe2fFVUSU6JRWK=
SK-NEP-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC5S4x4UUN3ME2wMlA5PjRzIN88US=> M4D3XnNCVkeHUh?=
NOMO-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmraTWM2OD1yLkC5Nlc2KM7:TR?= MV;TRW5ITVJ?
ES6 NYnnXWJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHYTWM2OD1yLkC5OVg6KM7:TR?= MX\TRW5ITVJ?
NCI-H209 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMEm3PFYh|ryP M3LvUXNCVkeHUh?=
GAK MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMUCxOkDPxE1? NX;yOI1[W0GQR1XS
BC-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ryUWlEPTB;MD6xNFM3OSEQvF2= NFzMUVdUSU6JRWK=
KLE NFfCXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DGcGlEPTB;MD6xNFQ1OyEQvF2= MoflV2FPT0WU
EW-3 NVXoV5RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMUC5PEDPxE1? M{HDO3NCVkeHUh?=
NKM-1 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLtTWM2OD1yLkGxNUDPxE1? M4LLeHNCVkeHUh?=
D-336MG NFr4fpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrCVlNbUUN3ME2wMlEyOjR2IN88US=> MmHqV2FPT0WU
NB69 NXXEVZZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm5TWM2OD1yLkGxN|AyKM7:TR?= MmG2V2FPT0WU
D-263MG MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CxXGlEPTB;MD6xNVcyOiEQvF2= MXvTRW5ITVJ?
KP-N-YS M4SzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIewc4VKSzVyPUCuNVIzQTFizszN M3;iSnNCVkeHUh?=
NCI-H1155 NIjuXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUK1OVgh|ryP NXi3e4s3W0GQR1XS
BOKU MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMUK1O|kh|ryP Ml\PV2FPT0WU
LAMA-84 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LlOWlEPTB;MD6xNlk6KM7:TR?= MYjTRW5ITVJ?
Raji MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M333[GlEPTB;MD6xN|EyPyEQvF2= MliwV2FPT0WU
LU-65 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\WTINKSzVyPUCuNVM{ODdizszN MlL4V2FPT0WU
NCI-H187 NULRWmROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEixT|ZKSzVyPUCuNVM6OjRizszN NYXwNW9wW0GQR1XS
GCIY NXzPPVlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHXTWM2OD1yLkG0PVAyKM7:TR?= NYixWJBiW0GQR1XS
NCI-H2107 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XUS2lEPTB;MD6xOVA5KM7:TR?= M3fLcnNCVkeHUh?=
NCI-H1522 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\STWM2OD1yLkG1NlY3KM7:TR?= NUPIOWxVW0GQR1XS
NB6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;pT5lKSzVyPUCuNVU3OjNizszN NVz6OmJtW0GQR1XS
EM-2 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvNbFNqUUN3ME2wMlE2PzB4IN88US=> MXjTRW5ITVJ?
HCC2218 NYr3bnFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMUW5PEDPxE1? NXLRcFRbW0GQR1XS
NCI-H748 NYnoU2U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMU[zO|Yh|ryP MkHMV2FPT0WU
MS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnkd25KSzVyPUCuNVY2OzdizszN M2P6e3NCVkeHUh?=
NB5 NFLDVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G3XWlEPTB;MD6xOlU6PyEQvF2= MXrTRW5ITVJ?
OMC-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTrTWM2OD1yLkG2Olg5KM7:TR?= NYTyc3pkW0GQR1XS
NCI-H345 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS4UFVKSzVyPUCuNVY6OjhizszN M{PVeHNCVkeHUh?=
L-428 M1;UWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXDUZVKSzVyPUCuNVY6PDVizszN M2\ZV3NCVkeHUh?=
SCH M2KyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTEb25OUUN3ME2wMlE5Pjh3IN88US=> NYHOPHBPW0GQR1XS
NCI-H1417 M1jhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHhTWM2OD1yLkG5NlI4KM7:TR?= NEXKNmpUSU6JRWK=
COLO-320-HSR MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMUm1N|Ih|ryP NVi3T4szW0GQR1XS
BT-474 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMkC4PVIh|ryP M{DJR3NCVkeHUh?=
GDM-1 NH\SSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMkG5O|Eh|ryP MXPTRW5ITVJ?
NCI-H2196 NGrnbIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMkKyN|Uh|ryP Mn3QV2FPT0WU
KP-N-RT-BM-1 NYntW5c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\xOmlEPTB;MD6yNlM1QSEQvF2= MmDkV2FPT0WU
KNS-81-FD MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnsTWM2OD1yLkKyPVU5KM7:TR?= MUfTRW5ITVJ?
COLO-668 M1r2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrPTWM2OD1yLkKzOlc2KM7:TR?= M2ryRnNCVkeHUh?=
C2BBe1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDYc5R4UUN3ME2wMlI3PzR5IN88US=> MWTTRW5ITVJ?
Ramos-2G6-4C10 NH[4fGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u4TmlEPTB;MD6yOlk2PCEQvF2= NYnac5R[W0GQR1XS
CAS-1 NYfROWNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMkewPVYh|ryP MUDTRW5ITVJ?
GOTO MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMke4PVQh|ryP MmO2V2FPT0WU
LP-1 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXiwPZdkUUN3ME2wMlI5ODV5IN88US=> MW\TRW5ITVJ?
NCI-SNU-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnFWXVCUUN3ME2wMlI6PDJ{IN88US=> NXzBd3d6W0GQR1XS
EB-3 M4rRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H0S2lEPTB;MD6yPVk4QSEQvF2= MnraV2FPT0WU
MHH-NB-11 M3f0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXMcZJKSzVyPUCuN|A1ODJizszN NY\rNXV{W0GQR1XS
SK-N-FI Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzCTWM2OD1yLkOxOlkzKM7:TR?= NH;acI5USU6JRWK=
HCC2157 NHriXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwM{O5NVMh|ryP MYPTRW5ITVJ?
SIMA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvsb5JnUUN3ME2wMlM1PThzIN88US=> M1fSPXNCVkeHUh?=
MDA-MB-134-VI M3e1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwM{[5Nlgh|ryP MYHTRW5ITVJ?
NCI-H1694 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHTOolKSzVyPUCuN|ch|ryP Mmr1V2FPT0WU
EHEB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLxdnZtUUN3ME2wMlM6ODh3IN88US=> MoG3V2FPT0WU
U-266 M4LENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zkPGlEPTB;MD6zPVg1PiEQvF2= Mn;hV2FPT0WU
LC-1F MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwNEO3OlUh|ryP NUfmUox4W0GQR1XS
SHP-77 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPFUIExUUN3ME2wMlQ4QDV3IN88US=> NFziN5BUSU6JRWK=
LS-513 NX73[Jl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK3TWM2OD1yLkS5N|A4KM7:TR?= MknRV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ:

[1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ

Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験:

[4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 3年-20℃
2年-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

文献中の引用 (16)

Frequently Asked Questions

  • Question 1
    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

    Answer: S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2
    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

    Answer: Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine

    Vincristine sulfateは一種の、チューブと結合することを通じて、マイクロチューブ重合を抑制する阻害剤で、無細胞試験でこのIC50値が32μMです。

  • Nocodazole

    Nocodazoleは一種のマイクロチューブ重合で、迅速可逆的な阻害剤で、無細胞試験でAbl、Abl(E255K)とAbl(T315I)を抑制する時のIC50値が0.21μM、0.53μMと0.64μMにそれぞれ分かれることです。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ